Eisai Co., Ltd. and Biogen Inc. have officially launched LEQEMBI, a groundbreaking treatment for Alzheimer’s disease, in South Korea. This follows its approval by the Ministry of Food and Drug Safety in May 2024, providing new hope for adult patients experiencing mild cognitive impairment or early-stage Alzheimer’s dementia.
LEQEMBI Targets Amyloid-Beta Aggregates
LEQEMBI, a humanized monoclonal antibody, effectively binds to both soluble and insoluble amyloid-beta (A) aggregates in the brain. By reducing protofibrils and amyloid plaques, LEQEMBI slows the progression of Alzheimer’s disease, offering a novel approach to mitigate cognitive and functional decline in patients. This makes LEQEMBI the first approved treatment in South Korea to demonstrate such efficacy in altering the disease’s trajectory.
Impact on South Korea’s Dementia Landscape
South Korea faces a significant burden with approximately 900,000 dementia patients as of 2021, where one in ten individuals over 65 suffers from dementia and one in five from mild cognitive impairment. Alzheimer’s dementia constitutes around 70% of these cases. The introduction of LEQEMBI is poised to alleviate both the personal and economic strain, with average annual care costs reaching up to 33.1 million KRW for severe cases. Eisai Korea Inc. will distribute LEQEMBI through the private market and implement a Patient Assistance Program to enhance accessibility and support for patients and their families.
Key Insights:
- LEQEMBI is the first South Korean-approved treatment to actively reduce amyloid-beta aggregates.
- The drug’s mechanism offers a tangible slowdown in Alzheimer’s progression, benefiting patients’ cognitive functions.
- Collaboration between Eisai and Biogen combines global expertise to enhance Alzheimer’s treatment options.
- Patient Assistance Programs aim to improve drug accessibility and support comprehensive care.
The strategic partnership between Eisai and Biogen underscores a commitment to advancing Alzheimer’s treatment through innovative therapies. By targeting the underlying amyloid-beta pathology, LEQEMBI not only addresses the symptoms but also the root causes of cognitive decline. This can lead to improved patient outcomes and reduced healthcare costs over time. Moreover, the proactive approach by Eisai Korea Inc. in raising disease awareness and fostering an ecosystem for early diagnosis and treatment highlights the importance of comprehensive strategies in managing Alzheimer’s disease.
Integrating LEQEMBI into South Korea’s healthcare system represents a significant step forward in the fight against Alzheimer’s. Patients can now access a treatment that not only alleviates symptoms but also slows disease advancement, potentially enhancing their quality of life. Caregivers and families will also benefit from reduced caregiving burdens and associated costs. As LEQEMBI gains traction, ongoing education and support initiatives will be crucial in maximizing its impact and ensuring that those affected by Alzheimer’s receive the best possible care and support.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
